Why Viking Therapeutics Is Set for a Major Breakthrough This November

Key Highlights

• Viking Therapeutics shares surged following J.P. Morgan's initiation of coverage with an "overweight" rating, signaling strong confidence in the company's prospects.
• The company's innovative weight-loss drugs have already driven significant stock gains this year, with analysts anticipating another boost soon.
• Long-term forecasts suggest Viking's oral weight-loss medication could capture around 10% of the market after its expected 2030 launch.

Shares of Viking Therapeutics (VKTX) jumped over 10% recently after J.P. Morgan analysts began coverage, assigning an "overweight" rating and highlighting the company's oral weight-loss drug in clinical trials as undervalued.

Positive clinical trial outcomes for Viking's weight-loss treatments, offered in both oral and injectable formats, have propelled the stock multiple times this year. Analysts believe another significant catalyst is on the horizon.

Upcoming Trial Data at Obesity Week Could Propel Viking Shares

Analysts point to the upcoming Obesity Week conference, scheduled for November 3-6 in San Antonio, Texas, as a key event where Viking may unveil new trial results demonstrating their drugs' effectiveness.

While Viking's injectable weight-loss drug faces stiff competition from established players like Eli Lilly and Novo Nordisk and is expected to hit the market around 2028, limiting its upside, the oral drug presents a more promising opportunity.

Viking’s Oral Weight-Loss Drug: A Game Changer

With an anticipated 2030 release, Viking's oral weight-loss medication is positioned to enter a competitive market with potentially fewer side effects compared to current alternatives, according to early trial data.

Analysts forecast this drug could secure approximately 10% market share in the years following its launch.

Additionally, a strategic partnership with a larger pharmaceutical firm could help Viking reduce development costs and expand its global reach in the rapidly growing weight-loss sector.

Viking Therapeutics' shares have nearly tripled since the start of the year, closing recently at $60.81 after an 11.3% increase.

Discover the latest news and current events in Markets News as of 16-09-2024. The article titled " Why Viking Therapeutics Is Set for a Major Breakthrough This November " provides you with the most relevant and reliable information in the Markets News field. Each news piece is thoroughly analyzed to deliver valuable insights to our readers.

The information in " Why Viking Therapeutics Is Set for a Major Breakthrough This November " helps you make better-informed decisions within the Markets News category. Our news articles are continuously updated and adhere to journalistic standards.